Compare Merck & Co., Inc. (MRK) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs BlackRock TCP Capital Corp — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while BlackRock TCP Capital Corp trades at $4.03 (market cap $341.90M). The key difference: Merck & Co., Inc. is far larger — about 1071.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.65%). Which is the better fit depends on your goals.
| MRK | TCPC | |
|---|---|---|
Market Cap | $366.28B | $341.90M |
Sector | Health | Financials |
52-Week High | $156.43 | $7.22 |
52-Week Low | $77.60 | $3.13 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | 18.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
TCPC trades at $4.07, showing no daily change. The stock exhibits bearish technical signals with flat support/resistance at $4. Recent earnings showed mixed results with Q2 2026 beating estimates at $0.22 EPS versus $0.20 expected. The company faces fundamental challenges with negative revenue of -$77.27M and net income of -$88.93M for 2025, though it maintains a dividend payout of $0.17 quarterly.
Investment outlook remains cautious due to negative profitability metrics and ongoing strategic review. The company's portfolio sale and leverage reduction provide some stability, but persistent revenue declines and class action lawsuits present significant risks. Analyst consensus leans neutral with 61.5% hold ratings, reflecting uncertainty about the company's turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
